(Q86454230)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26460357%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

Diabetic nephropathy: Nonsteroidal MRA added to RAS blockade reduces albuminuria (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26460357%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

Matthew R Weir

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26460357%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

13 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26460357%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Nephrology

26 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26460357%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26460357%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26460357%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

691-692

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26460357%20AND%20SRC:MED&resulttype=core&format=json

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial

26 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2015.167

Proteinuria should be used as a surrogate in CKD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2015.167

Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2015.167

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2015.167

Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2015.167

Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2015.167

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2015.167

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2015.167

Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2015.167

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2015.167

31 March 2020

Identifiers

DOI

10.1038/NRNEPH.2015.167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26460357%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference